To include your compound in the COVID-19 Resource Center, submit it here.

GW320659: Phase II

In an open-label 51-patient U.S. Phase II study of 7 doses

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE